Compare SPAI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPAI | ANIX |
|---|---|---|
| Founded | 2021 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7M | 114.0M |
| IPO Year | 2024 | 2013 |
| Metric | SPAI | ANIX |
|---|---|---|
| Price | $4.46 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.00 | $8.67 |
| AVG Volume (30 Days) | 104.9K | ★ 332.0K |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $606,681.00 | $210,000.00 |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.23 | $2.32 |
| 52 Week High | $9.04 | $5.46 |
| Indicator | SPAI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 34.11 |
| Support Level | $4.35 | $2.37 |
| Resistance Level | $4.74 | $3.09 |
| Average True Range (ATR) | 0.36 | 0.19 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 19.23 | 14.02 |
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.